Randomized Controlled Trial of Moderate-Intensity Rosuvastatin With Ezetimibe Combination Therapy Versus High-Intensity Rosuvastatin on Progression of Coronary Atherosclerotic Plaque

NCT03169985 · clinicaltrials.gov ↗

PHASE4

Phase

ACTIVE_NOT_RECRUITING

Status

280

Enrollment

OTHER

Sponsor class

Conditions

Coronary Artery Disease

Interventions

DRUG: Rosuvastatin 10 mg plus ezetimibe 10 mg orally once a day
DRUG: Rosuvastatin 20 mg orally once a day

Sponsor

Samsung Medical Center

Collaborators

[object Object]